Working… Menu

Efficacy of Ramelteon in Adults With Chronic Insomnia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00672724
Recruitment Status : Terminated (Issues with data collection tool)
First Posted : May 6, 2008
Last Update Posted : February 28, 2012
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate subjectively reported treatment effects of ramelteon, once daily (QD), in adults with chronic insomnia.

Condition or disease Intervention/treatment Phase
Chronic Insomnia Drug: Ramelteon Drug: Placebo Phase 3

Detailed Description:

Insomnia is characterized by difficulties initiating and maintaining sleep, or complaints of non-restorative and non-refreshing sleep. Transient insomnia affects approximately one-third to one-half of the US population, based on the results of 2 surveys of representative samples of the adult US population conducted by the Gallup Organization in which respondents were asked if they had "ever had difficulty sleeping." Based on reports of "regular" or "frequent" sleep difficulty, results from the same studies suggest that approximately one-tenth of the US population experiences chronic insomnia. The ideal treatment for insomnia would reduce the latency to onset of sleep and increase total sleep time, without a negative impact on sleep architecture and without safety concerns or next-day effects.

Ramelteon is under global development by Takeda Chemical Industries, Ltd., for the treatment of transient and chronic insomnia and for the treatment of Circadian Rhythm Sleep Disorders.

This study is being conducted to assess the treatment effects of ramelteon in adults through the use of daily entry of information into an interactive voice response system. Study participation in this study is anticipated to be about 1 month.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1081 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Subjective Response to Treatment With Ramelteon in Adult Subjects With Chronic Insomnia by Utilizing an Interactive Voice Response System (IVRS) for Collecting Diary Data
Study Start Date : February 2005
Actual Primary Completion Date : August 2005
Actual Study Completion Date : August 2005

Resource links provided by the National Library of Medicine

Drug Information available for: Ramelteon

Arm Intervention/treatment
Experimental: Ramelteon 8 mg QD Drug: Ramelteon
Ramelteon 8 mg tablets, taken orally, once daily for up to 2 weeks.
Other Names:
  • Rozerem™
  • TAK-375

Placebo Comparator: Placebo Drug: Placebo
Ramelteon placebo-matching tablets, taken orally, once daily for up to 2 weeks.

Primary Outcome Measures :
  1. Mean Subjective Sleep Latency determined through subject responses on morning questionnaire. [ Time Frame: Day 8 ]

Secondary Outcome Measures :
  1. Mean Subjective Sleep Latency. [ Time Frame: Day 15 ]
  2. Mean Subjective Total Sleep [ Time Frame: Day 8 ]
  3. Mean Subjective Total Sleep [ Time Frame: Day 15 ]
  4. Adverse Events. [ Time Frame: Days 1, 8, and 15 or Final Visit. ]
  5. Clinical Laboratory Tests Hematology [ Time Frame: Day 15 or Final Visit. ]
  6. Clinical Laboratory Tests Chemistry. [ Time Frame: Day 15 or Final Visit. ]
  7. Clinical Laboratory Tests Urinalysis [ Time Frame: Day 15 or Final Visit. ]
  8. Vital Signs. [ Time Frame: Days 8 and 15 or Final Visit. ]
  9. Electrocardiograms. [ Time Frame: Day 15 or Final Visit. ]
  10. Physical Examinations. [ Time Frame: Day 15 or Final Visit. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
  • Has had primary chronic insomnia as defined by Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised for at least 3 months.
  • Reports a history of subjective sleep latency greater than or equal to 60 min and a subjective total sleep time less than 6.5 hours.
  • Habitual bedtime is between 10:00 PM and 1:00 AM.
  • Willing to have a fixed bedtime and agrees to go to bed within plus or minus 30 minutes of the habitual bedtime during the entire study.
  • Consistent access to a touch tone phone and are willing to complete telephone questionnaires twice daily during participation in the study.
  • Willing to remain in bed for at least 6.5 hours each night during the entire study.
  • Used pharmacological assistance to sleep 0-4 times per week in the last 3 months.
  • Must complete the morning questionnaire on at least 4 of the first 7 mornings after Screening Visit 1.
  • On at least 3 of the first 5 nights of single-blind placebo treatment, the subject must have a subjective sleep latency of greater than or equal to 45 minutes.
  • On at least 3 of the first 5 nights of single-blind placebo treatment, the subject must have a subjective total sleep time of less than 6.5 hours.

Exclusion Criteria

  • Known hypersensitivity to ramelteon or related compounds, including melatonin, and 5-hydroxytryptophan.
  • Participated in any other investigational study and/or took any investigational drug within 30 days prior to the first dose of single-blind study medication.
  • Sleep schedule changes required by employment (eg, shift worker) within 3 months prior to the first night of single-blind study medication.
  • Has flown across greater than 3 time zones within 7 days prior to screening, or will travel across 2 or more time zones during the course of the study.
  • Participated in a weight loss program or has substantially altered exercise routine within 30 days prior to the first night of singleblind study medication.
  • Ever had a history of seizures, sleep apnea, and/or chronic obstructive pulmonary disease.
  • History of psychiatric disorder within the past 6 months.
  • History of fibromyalgia.
  • History of drug addiction or drug abuse within the past 12 months.
  • History of alcohol abuse within the past 12 months, as defined in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised and/or regularly consumes more than 2 alcoholic drinks per day.
  • Current significant hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematologic, or metabolic disease, unless currently controlled and stable with protocol-allowed medication, within 30 days prior to the first night of single-blind study medication.
  • Uses tobacco products or any other products that may interfere with the sleep wake cycle during nightly awakenings.
  • Any clinically important abnormal finding as determined by a medical history, physical examination, electrocardiogram, or clinical laboratory tests, as determined by the investigator.
  • Positive hepatitis panel.
  • Any additional condition(s) that in the Investigator's opinion would:

    • affect sleep/wake function
    • prohibit the subject from completing the study
    • indicate that continuation in the study would not be in the best interests of the subject.
  • Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication, including:

    • Anxiolytics
    • Central nervous system active drugs
    • Hypnotics
    • Narcotic analgesics
    • Antidepressants
    • Beta blockers
    • Anticonvulsants
    • St. John's Wort
    • Sedating H1 antihistamines
    • Kava-kava
    • Systemic steroids
    • Ginkgo-biloba
    • Respiratory stimulants
    • Over-the-counter and prescriptions stimulants
    • Decongestants
    • Over-the-counter and prescription diet aids
    • Antipsychotics
    • Melatonin and all other drugs or supplements known to affect sleep/wake

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00672724

Layout table for location information
United States, Arizona
Mesa, Arizona, United States
Phoenix, Arizona, United States
Scottsdale, Arizona, United States
United States, Arkansas
Hot Springs, Arkansas, United States
United States, California
Cerritos, California, United States
La Jolla, California, United States
La Mesa, California, United States
Oakland, California, United States
United States, Colorado
Denver, Colorado, United States
United States, Florida
Bay Harbor Island, Florida, United States
Brandon, Florida, United States
Clearwater, Florida, United States
Deland, Florida, United States
Fort Lauderdale, Florida, United States
Fort Myers, Florida, United States
Hollywood, Florida, United States
Miami, Florida, United States
Pembroke Pines, Florida, United States
Pinellas Park, Florida, United States
Vero Beach, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
Austell, Georgia, United States
Macon, Georgia, United States
United States, Idaho
Boise, Idaho, United States
United States, Illinois
Northbrook, Illinois, United States
United States, Kansas
Prairie Village, Kansas, United States
Wichita, Kansas, United States
United States, Kentucky
Louisville, Kentucky, United States
United States, Maryland
Frederick, Maryland, United States
United States, New Jersey
Moorestown, New Jersey, United States
United States, New York
Menlius, New York, United States
New York, New York, United States
Williamsville, New York, United States
United States, North Carolina
Salem, North Carolina, United States
Winston-Salem, North Carolina, United States
United States, Ohio
Cincinnati, Ohio, United States
Mogadore, Ohio, United States
United States, Pennsylvania
Philadelphia, Pennsylvania, United States
United States, Tennessee
Bristol, Tennessee, United States
Chattanooga, Tennessee, United States
United States, Texas
Dallas, Texas, United States
United States, Virginia
Fairfax, Virginia, United States
United States, Washington
Tacoma, Washington, United States
Sponsors and Collaborators
Layout table for investigator information
Study Director: VP Clinical Science Takeda
Additional Information:
Layout table for additonal information
Responsible Party: Takeda Identifier: NCT00672724    
Other Study ID Numbers: 01-04-TL-375-041
U1111-1114-2738 ( Registry Identifier: WHO )
First Posted: May 6, 2008    Key Record Dates
Last Update Posted: February 28, 2012
Last Verified: February 2012
Keywords provided by Takeda:
Sleep Disorder
Drug Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Sleep Initiation and Maintenance Disorders
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases
Mental Disorders